• Daria Mochly-Rosen, PhD
    Daria Mochly-Rosen, PhDFounder, SAB Chair

    Daria Mochly-Rosen, Professor of Chemical and Systems Biology, is the George D. Smith Professor for Translational Medicine and the co-director of SPARK at Stanford. Daria leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists and has used her basic research discoveries to develop a number of drug leads for human diseases with a particular interest in mitochondrial biology and pathology. The reseach in her lab led to the identification of a novel inhibitor of pathological mitochondrial fission, and its use in a variety of chronic diseases, including neurodegeneration. This technology provided the basis for Mitoconix, which she founded in FutuRx in 2016.

    She was the chair of her department (2001-2004) and Senior Associate Dean for Research (2013-2016), has published over 250 papers, over 30 patents and founded two other companies: KAI Pharmaceuticals (2003-2011, the maker of Parsabiv for kidney dialysis patients; aquiered by Amgen and sold by Amgen and Ono since 2016), ALDEA/Aviv (2013; now licensed to Foresee).

    Daria is also the founder, president and co-director of SPARK At Stanford (since 2006), which provides education in drug discovery and development and has helped over 100 inventors (60% of the participants) of biopharmaceuticals and diagnostics bring their invention to clinical studies and/or to licensing. She is the president founder of SPARKGlobal, which help establish SPARK programs in >50 academic institutions around the world, increasing the likelihood that new treatments will be developed from academic research efforts across the globe.

    Dr. Mochly-Rosen holds a Ph.D. in Chemical Immunology from the Weizmann Institute of Science in Israel, and completed her postdoctoral training at University of California, Berkeley.

    • Erez Chimovits
      Erez ChimovitsChairman of the Board

      Erez has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed Erez was the CEO of NasVax (TASE:NSVX). NasVax acquired Protea and struck agreements with GlaxoSmithKline and Novartis. Previously, Erez spent more than seven years with Compugen (Nasdaq:CGEN), as President, Compugen USA Inc. and Executive VP, Commercial Operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including J&J, Novartis, Teva, Abbott, Medarex and others. Erez earned his M.B.A., M.Sc. in Microbiology and his B.Sc. from Tel Aviv University.

      • Taro Inaba
        Taro InabaDirector

        Taro Inaba is Founder and Managing Partner at Remiges Ventures a US based cross-boarder venture capital firm established in 2014. Prior to this, he spent more than 10 years at Mitsui & Co., Ltd. in the venture investment field during which time he generated number of successful investment deals and held positions as a board member in more than 10 portfolio companies. While at Mitsui, he built the biopharma investment team and infrastructure and served as President & CEO at Mitsui Ventures in Menlo Park, California from 2008 to 2009. Prior to Mitsui Ventures Taro spent 10 years in various capacities at Mitsui & Co. Ltd, including extensive experience in business development roles. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University. He is a CFA charter holder.

        • Tetsu Maruyama
          Tetsu MaruyamaDirector

          Academic credentials:PhD from Stanford University, post-doctoral at Yale University.
          Tetsu Maruyama is Chief Scientific Officer for the DDF. Tetsu’s background is in neuroscience, after a 15-year academic career with faculty positions at the University of Minnesota in the US and Cardiff University in the UK, Tetsu moved to industry, first at Merck Sharpe and Dohme’s Neuroscience Research Centre in the UK and then at GSK, where he was the Director of the GSK Centre for Cognitive and Neurodegenerative Disorders in Singapore. In 2006 he moved to Takeda Pharmaceutical Company in Japan, first as Head of CNS Research and then as Head of Global Drug Discovery, a position he held until his appointment to DDF.